NICE: no evidence to approve Merck Serono's Erbitux, Roche's Avastin and Amgen's Vectibix for second-line mCRC
This article was originally published in Scrip
Executive Summary
Merck Serono's Erbitux (cetuximab), Roche's Avastin (bevacizumab) and Amgen's Vectibix (panitumumab) have failed to win recommendations from NICE, the health technology appraisal institute for England and Wales, for the treatment of metastatic colorectal cancer that has progressed after first-line chemotherapy.